Ebert, R.

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 1,651

Reduced incretin effect in Type 2 (non-insulin dependent) diabetes

Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 1,307

Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses

NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 874

Preservation of incretin activity after removal of gastric inhibitory polypeptide (GIP) from rat gut extracts by immunoadsorption

Ebert, R., Unger, H., & Creutzfeldt, W. (1983) · Diabetologia

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 120